Different treatment strategy based on tumor etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-positive HCC patients may be the best strategy for improvement the outcome of these patients
Casadei Gardini A, F.G. (2017). Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials. DIGESTIVE AND LIVER DISEASE, 49, 943-944 [10.1016/j.dld.2017.04.022].
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.
Ercolani GSupervision
;Ulivi P.Data Curation
2017
Abstract
Different treatment strategy based on tumor etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-positive HCC patients may be the best strategy for improvement the outcome of these patientsFile in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
